ARQT News and Press, Arcutis Biotherapeutics Inc. From 05/13/24

2024-05-13 17:35:40 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics: Betting Big On Zoryve Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript Arcutis announces pricing of $150 million public offering Arcutis licenses Japanese rig...

Eight of nine experts expressed feeling “extremely confident” about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation data Crodafos™ CES, used in ZORYVE foam, is suitab...

2024-05-07 10:47:03 ET ProShares UltraPro Short QQQ (SQQQ) SQQQ is trading DOWN for the last 4 days, and it at trading at $10.69 with volume of 30,905,666 and a one day change of $-0.01 (-0.09%). ProShares UltraPro Short QQQ has a 52-week low of 10.05 and a 52-week high of $29.28. T...

2024-05-01 06:57:02 ET Summary Arcutis Biotherapeutics is a biopharmaceutical company focused on developing therapies for dermatological diseases. The company has received FDA approval for its drug Zoryve and is expecting further label expansions and approvals. While the compa...

WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2024 financial results ...

2024-04-10 08:16:17 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture Arcutis announces pricing of $150 million public offering Arcutis lice...

WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper has been appointed Chief Financial Officer (CFO) effe...

NESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved lar...

WESTLAKE VILLAGE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the 23 rd ...

Industry veteran with over 25 years’ experience will continue to advance the company culture and grow the capabilities of Arcutis’ workforce WESTLAKE VILLAGE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage ...